Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Cervical Cancer Screening with MRI and PET/CT Improves Treatment Chances

By HospiMedica International staff writers
Posted on 25 Mar 2009
Pretreatment screening with magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) for cervical cancer may lead more women to optimal therapy choices and spare many women potential long-term morbidity and complications of trimodality therapy (surgery followed by chemoradiation), according to a recent study.

An interdisciplinary team of investigators from the Institute for Technology Assessment (Boston, MA, USA) developed a decision-analytic model to determine the benefits of pretreatment imaging with MRI and/or PET/CT in patients with FIGO stage IB cervical cancer. More...
"Stage IB cervical cancer, in the absence of pretreatment imaging, is treated with surgery. As surgery cannot completely resect the cancer in many of these patients, they receive postsurgical chemoradiation, i.e., trimodality therapy,” said Pari Pandharipande, M.D., and lead author of the study. "The goal of pretreatment imaging is to identify these patients noninvasively, spare them surgery, and have them treated with chemoradiation alone,” she said.

The study's findings demonstrated that while imaging does not improve survival, PET/CT resulted in the highest percentage of patients receiving appropriate primary therapy (89%) and use of both MRI and PET/CT spared the most patients of trimodality therapy (95%).

According to Dr. Pandharipande, pretreatment imaging can provide patients with the best primary treatment choices that minimize the risk of long-term complications and morbidity while safeguarding chances for survival. She added that because both over- and underestimation level of disease can result in unfavorable patient outcomes, determining the extent of disease accurately immediately is crucial. For example, when patients are subjected to pelvic surgery, and then are radiated in the same operative field, complication rates can increase by a considerable proportion, as compared to if they were just treated with surgery alone or chemoradiation alone.

Dr. Pandharipande reported that this study demonstrates how pretreatment imaging may improve chances of successfully receiving surgery or chemoradiation instead of both. "MRI and PET/CT are expensive, but long-term consequences of trimodality therapy can severely affect long-term quality of life and are also expensive. Further study of these long-term consequences is needed to more precisely consider the cost implications of upfront MRI and PET/CT. Currently there are no specific guidelines that prescribe MRI or PET/CT for determining a plan of action for the treatment of stage IB cervical cancer patients. It remains important for patients to make imaging and treatment decisions with their gynecologic-oncologist on a case-by-case basis,” stated Dr. Pandharipande. "My goal as a researcher in radiology is to continue to objectively look at what we do and how it impacts patient care. A better understanding of what happens to people after they receive imaging tests both improves patient care directly and focuses further research efforts in areas most influential to patient outcomes.”

This study appears in the March 2009 issue of the American Journal of Roentgenology (AJR).

Related Links:
Institute for Technology Assessment



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.